

**AMENDMENTS TO THE DRAWINGS**

The attached sheets (3) of drawings includes changes to Fig. 9. These sheets, which include Fig. 9 (A), (B) and (C), replace the original sheet including Fig. 9. (A), (B) and (C). In Fig. 9 (C), previously omitted 3' end of the open reading frame sequence has been added.

Attachment: Replacement Sheets (3)

### **REMARKS**

The specification is corrected for Fig. 9 and Replacement Sheets for Fig. 9(A), (B) and (C) are submitted to replace the original sheet including Fig. 9(A), (B) and (C). SEQ ID NO:13 of Fig. 9(C) is the open reading frame of SEQ ID NO:11 in Fig. 9(A). See paragraph [20] on page 5 of the specification. The 3' end of the open reading frame sequence (SEQ ID NO:13) in the originally submitted Fig. 9(C) was inadvertently cut-off. That is, 243 nucleotides follow at the 3'-end of originally filed SEQ ID NO:13 (cuts-off with "gttgct") to complete the open reading frame. In addition, the stop codon (tga) including the remaining sequence of SEQ ID NO:11 (172 nucleotides) was cut-off in the originally filed Fig. 9(C).

Support to amend Fig. 9(C) to add the last 243 nucleotides to complete the open reading frame of SEQ ID NO:13 and the rest of the sequence thereafter (172 nucleotides) is provided in Fig. 9(A) and (B). Fig. 9(A) provides the nucleotide sequence and Fig. 9(B) provides the amino acid sequence of SEQ ID NO:13. Further, SEQ ID NO:11 in Fig. 9(A) provides the start and stop codons which identifies the open reading frame of the SEQ ID NO:13. See paragraph [20] on page of the specification. Therefore, the omitted 243 nucleotides from originally submitted SEQ ID NO:13 of Fig. 9(C) correspond to nucleotides 602-844 of SEQ ID NO:11 in Fig. 9(A). SEQ ID NO:11 in Fig. 9(A) also provides the remaining 172 nucleotides of the sequence. Therefore, the omitted remaining 172 nucleotides from originally submitted SEQ ID NO:13 of Fig 9(C) correspond to nucleotides 845-1016 of SEQ ID NO:11. Accordingly, Applicants respectfully submit that no new matter has been added, and respectfully request entry of the Replacement Sheets.

The specification is further corrected and a Sequence Listing is herein submitted to comply with the requirements of an application containing a nucleotide and/or amino acid sequence 37 C.F.R. §§ 1.821 - 1.825.

The paper copy and computer readable copy of the Sequence Listing are the same. For the reasons presented above for the Replacement Sheets for Fig. 9, and otherwise, the Sequence Listing does not include new matter.

### **CONCLUSION**


Entry of the Sequence Listing and the Replacement Sheets for Fig. 9, corrections to the specification, and favorable consideration are respectfully requested.

**To the extent necessary, please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees, to Deposit Account 500417.**

Respectfully submitted,  
McDERMOTT, WILL & EMERY LLP

Date: March 10, 2005

By:

  
Kelli N. Watson  
Registration No. 47,17

600 Thirteenth Street, N.W.  
Washington, D.C. 20005-3096  
(202) 756-8351 (Direct)  
(202) 756-8087 (Facsimile)  
WDC99 1043352-1.050229.0424